Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8466137 | ABBVIE | Testosterone gel and method of use |
Oct, 2026
(3 years from now) | |
US8754070 | ABBVIE | Testosterone gel and method of use |
Oct, 2026
(3 years from now) | |
US8729057 | ABBVIE | Testosterone gel and method of use |
Oct, 2026
(3 years from now) | |
US8741881 | ABBVIE | Testosterone gel and method of use |
Oct, 2026
(3 years from now) | |
US8466138 | ABBVIE | Testosterone gel and method of use |
Oct, 2026
(3 years from now) | |
US8466136 | ABBVIE | Testosterone gel and method of use |
Oct, 2026
(3 years from now) | |
US8486925 | ABBVIE | Testosterone gel and method of use |
Oct, 2026
(3 years from now) | |
US8759329 | ABBVIE | Testosterone gel and method of use |
Oct, 2026
(3 years from now) |
Market Authorisation Date: 29 April, 2011
Treatment: Testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone
Dosage: GEL, METERED;TRANSDERMAL; GEL;TRANSDERMAL
14
United States
3
European Union
2
Denmark
2
Slovenia
2
Norway
2
Portugal
2
Cyprus
2
Spain
2
Poland
2
Japan
1
Israel
1
South Africa
1
Turkey
1
Australia
1
Hong Kong
1
Lithuania
1
Morocco
1
Croatia
1
Brazil
1
Korea, Republic of
1
RS
1
China
1
Ecuador
1
Georgia
1
Ukraine
1
EA
1
Canada
1
Tunisia
1
New Zealand
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8784878 | ELI LILLY AND CO | Transdermal delivery rate control using amorphous pharmaceutical compositions |
Jul, 2023
(3 months from now) | |
US9180194 | ELI LILLY AND CO | Method and composition for transdermal drug delivery |
Jun, 2026
(3 years from now) | |
US8993520 | ELI LILLY AND CO | Method and composition for transdermal drug delivery |
Jun, 2026
(3 years from now) | |
US8419307 | ELI LILLY AND CO | Spreading implement |
Feb, 2027
(3 years from now) | |
US8807861 | ELI LILLY AND CO | Spreading implement |
Feb, 2027
(3 years from now) | |
US9289586 | ELI LILLY AND CO | Spreading implement |
Feb, 2027
(3 years from now) | |
US8435944 | ELI LILLY AND CO | Method and composition for transdermal drug delivery |
Sep, 2027
(4 years from now) |
Market Authorisation Date: 23 November, 2010
Treatment: A method of transdermally delivering testosterone; A method of increasing the testosterone blood level of an adult male subject in need thereof; A method of increasing the testosterone blood level of ...
Dosage: SOLUTION, METERED;TRANSDERMAL
16
United States
8
Australia
5
Japan
5
Korea, Republic of
4
European Union
3
Brazil
3
EA
3
Canada
3
New Zealand
3
China
2
Hong Kong
2
South Africa
2
Mexico
2
Spain
1
India
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8784882 | ACERUS | Controlled release delivery system for nasal applications and method of treatment |
Feb, 2024
(10 months from now) | |
US8877230 | ACERUS | Controlled release delivery system for nasal applications |
Feb, 2024
(10 months from now) | |
US8574622 | ACERUS | Controlled release delivery system for nasal applications |
Feb, 2024
(10 months from now) | |
US8784869 | ACERUS | Controlled release delivery system for nasal applications and methods of treatment |
Feb, 2024
(10 months from now) | |
US11090312 | ACERUS | Methods of treating hypogonadism with transnasal testerosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event |
Mar, 2034
(10 years from now) |
Market Authorisation Date: 28 May, 2014
Treatment: A method of testosterone replacement therapy comprising the step of nasally administering to a patient in need of such treatment an effective amount of testosterone gel formulation.; Nasal administrat...
Dosage: GEL, METERED;NASAL
32
United States
2
IB
2
European Union
1
South Africa
1
Denmark
1
Austria
1
Australia
1
Russia
1
Slovenia
1
Norway
1
Germany
1
Argentina
1
Brazil
1
Croatia
1
Portugal
1
Malaysia
1
Spain
1
Korea, Republic of
1
Poland
1
Taiwan, Province of China
1
Japan
1
Canada
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7608605 | AUXILIUM PHARMS LLC | Pharmaceutical composition |
Apr, 2023
(18 days from now) | |
US7608610 | AUXILIUM PHARMS LLC | Pharmaceutical composition |
Apr, 2023
(18 days from now) | |
US7608608 | AUXILIUM PHARMS LLC | Pharmaceutical composition |
Apr, 2023
(18 days from now) | |
US7608606 | AUXILIUM PHARMS LLC | Pharmaceutical composition |
Apr, 2023
(18 days from now) | |
US8063029 | AUXILIUM PHARMS LLC | Pharmaceutical composition |
Apr, 2023
(18 days from now) | |
US8178518 | AUXILIUM PHARMS LLC | Pharmaceutical composition |
Apr, 2023
(18 days from now) | |
US7935690 | AUXILIUM PHARMS LLC | Pharmaceutical composition |
Apr, 2023
(18 days from now) | |
US7608609 | AUXILIUM PHARMS LLC | Pharmaceutical composition |
Apr, 2023
(18 days from now) | |
US7608607 | AUXILIUM PHARMS LLC | Pharmaceutical composition |
Apr, 2023
(18 days from now) | |
US7320968 | AUXILIUM PHARMS LLC | Pharmaceutical composition |
Jan, 2025
(1 year, 9 months from now) |
Market Authorisation Date: 31 October, 2002
Treatment: Method for administration of testosterone
Dosage: GEL;TRANSDERMAL
23
United States
3
Hong Kong
2
Argentina
2
Spain
2
Korea, Republic of
2
Iceland
2
China
2
European Union
1
Israel
1
South Africa
1
Denmark
1
Austria
1
Mexico
1
Australia
1
Egypt
1
Saudi Arabia
1
Lithuania
1
Latvia
1
Norway
1
Germany
1
Brazil
1
Cyprus
1
Malaysia
1
Poland
1
Taiwan, Province of China
1
Japan
1
EA
1
Canada
1
New Zealand
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9662340 | UPSHER SMITH LABS | Testosterone gel compositions and related methods |
Feb, 2034
(10 years from now) | |
US9295675 | UPSHER SMITH LABS | Testosterone gel compositions and related methods |
Feb, 2034
(10 years from now) | |
US8785426 | UPSHER SMITH LABS | Testosterone gel compositions and related methods |
Feb, 2034
(10 years from now) |
Market Authorisation Date: 04 June, 2014
Treatment: Method for transdermal delivery of testosterone
Dosage: GEL, METERED;TRANSDERMAL; GEL;TRANSDERMAL
5
United States
1
Hong Kong
1
Singapore
1
South Africa
1
Canada
1
Australia
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic